AVAV vs. VRNA

Last updated Jun 9, 2026

AVAV (AeroVironment, Inc.) and VRNA (Verona Pharma plc) are both stocks. AVAV operates in Aerospace & Defense (Industrials), while VRNA operates in Biotechnology (Healthcare). At a 0.10 correlation, their price movements are largely independent.

Performance

AVAV vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AeroVironment, Inc. (AVAV) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

AVAV

• 1D: -0.67%
• 1M: 9.74%
• YTD: -23.65%
• 6M: -34.62%
• 1Y: -3.25%
• 3Y*: 23.54%
• 5Y*: 10.87%
• 10Y*: 19.16%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

AVAV vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AVAV AeroVironment, Inc.	-23.65%	57.18%	22.10%	47.14%	38.09%	-28.62%	40.75%	-9.14%	20.99%	90.50%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between AVAV and VRNA is -0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.01
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.13
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.10

The correlation between AVAV and VRNA shifts across timeframes, from -0.01 (1 year) to 0.13 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap AVAV : $9.01B VRNA : $9.72B
EPS AVAV : -$4.63 VRNA : -$0.69
PS Ratio AVAV : 7.51 VRNA : 57.97
PB Ratio AVAV : 2.11 VRNA : 34.92
Total Revenue (TTM) AVAV : $1.19B VRNA : $167.65M
Gross Profit (TTM) AVAV : $104.63M VRNA : $159.52M
EBITDA (TTM) AVAV : -$242.06M VRNA : -$40.86M

Return for Risk

AVAV vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AVAV

AVAV Risk / Return Rank: 41
AVAV Sharpe Ratio Rank: 40
AVAV Sortino Ratio Rank: 43
AVAV Omega Ratio Rank: 42
AVAV Calmar Ratio Rank: 41
AVAV Martin Ratio Rank: 40

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AVAV vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AeroVironment, Inc. (AVAV) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AVAV	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.04	—	—
Sortino ratio: Return per unit of downside risk	0.48	—	—
Omega ratio: Gain probability vs. loss probability	1.06	—	—
Calmar ratio: Return relative to maximum drawdown	-0.05	—	—
Martin ratio: Return relative to average drawdown	-0.10	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	AVAV	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.04	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.20	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.37	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.23	—	—

Drawdowns

Drawdown Indicators

	AVAV	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-61.45%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-61.45%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-61.45%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-61.45%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-61.45%	—	—
Current Drawdown Current decline from peak	-54.94%	—	—
Average Drawdown Average peak-to-trough decline	-28.56%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	33.68%	—	—

Volatility

Volatility by Period

	AVAV	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.99%	—	—
Volatility (6M) Calculated over the trailing 6-month period	58.60%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	73.83%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.85%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	51.96%	—	—

Dividends

AVAV vs. VRNA - Dividend Comparison

Neither AVAV nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both AVAV and VRNA in my portfolio?

AVAV and VRNA have a correlation of -0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.